日本药企卫材将在中国销售乙肝药克拉夫定

MP4

http://cn.nikkei.com/industry/manufacturing/1367-20120206.html
2012/02/06
       日本医药企业卫材公司最早将在2012年度在中国销售慢性乙肝治疗药。该药是一种可以降低病毒增殖所必须的酶的活性的抗病毒药剂。中国的乙肝患者预测将达1200万人，对该药将出现很大需求。该公司认为中国的销售额在2015年度以前将以平均每年26%的速度快速增长，因此将加速扩充在中国推出的产品种类。

       该药药名为克拉夫定，是一种口服药剂，卫材从韩国另一家制药公司富光制药手中，取得了包括中国在内的8个亚洲国家及地区的开发、销售和制造权，目前正在进行产品研发。据悉，克拉夫定具有抑制DNA（脱氧核糖核酸）合成所必须的“DHA聚合酶”的活性的功效，而病毒的增殖过程中必须进行DNA合成。早在2010年2月该药就以产品名“Levovir”在菲律宾上市。目前除中国以外，还在印度尼西亚、泰国、越南和印度等地申请审批。该公司预计不久将在中国取得国家食品药品监督管理局颁发的进口许可证，届时中国将成为继菲律宾之后第二个销售该药品的国家。

       卫材将通过子公司卫材（苏州）贸易在中国进行销售。目前，除了治疗痴呆症的主力药“Aricept”之外，卫材还在中国销售抗溃疡药“波力特”和由糖尿病等原因引发的末梢神经障碍治疗药“甲钴胺”等药品，并配备了约800名医药信息。卫材在中国的业务，最初由癌症、消化系统、肝脏和中枢神经等4块专门业务发展而来，尤其是在肝脏疾病和癌症领域，颇具实力。

       另据悉，该公司2月2日公布的2011年4～12月的合并结算显示，与上一年同期相比，销售额和纯收益为5048亿日元和491亿日元，分别下降了17.8%和27.0%。在美国，由于Aricept的专利权过期，加之与新药的竞争日益激烈，销售额出现持续下滑。而另一方面，该公司在中国的销售额达130亿日元，同比增长23.8%，包括日本和中国在内的东亚地区的销售额也达3157亿日元，同比增长近10%。

咬牙硬挺

rep网站的新消息REPLICor to disclose interim REP 9AC / 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012)
22-25 June 2012, Shanghai International Convention Center, Shanghai,  China.
Montreal, Quebec – Friday, June 22nd, 2012 – REPLICor will disclose updated interim results and metadata analysis of antiviral responses in patients with chronic hepatitis B who are enrolled in its proof of concept clinical trials of REP 9AC and REP 9AC’for the treatment of chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012) currently being held from 22-25th of June.  This important meeting, held only once every three years, is the preeminent meeting focusing on viral hepatitis and attracts key academicians and physicians working to improve the treatment outlook for patients with viral hepatitis.
REP 9AC’ represents the latest clinicalcandidate in a new class of antiviral agents, nucleic acid polymers (or NAPs) that block the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. Metadata analysis of patients on REP 9AC or REP 9AC’ demonstrates that serum HBsAg can be routinely eliminated in 12-16 weeks and is followed by a restoration in the patient’s immune response, resulting in a substantial elimination of virus from the blood of patients.  REPLICor will present updated clinical efficacy results and metadata analysis of antiviral responses in patients receiving REP 9AC or REP 9AC’ in an oral presentation on Sunday June 24th, 2012.
For the 14th International Symposium of Viral Hepatitis and Liver Disease see: http://www.isvhld2012.org/isvhld.html

咬牙硬挺

rep网站的新消息REPLICor to disclose interim REP 9AC / 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012)
22-25 June 2012, Shanghai International Convention Center, Shanghai,  China.
Montreal, Quebec – Friday, June 22nd, 2012 – REPLICor will disclose updated interim results and metadata analysis of antiviral responses in patients with chronic hepatitis B who are enrolled in its proof of concept clinical trials of REP 9AC and REP 9AC’for the treatment of chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012) currently being held from 22-25th of June.  This important meeting, held only once every three years, is the preeminent meeting focusing on viral hepatitis and attracts key academicians and physicians working to improve the treatment outlook for patients with viral hepatitis.
REP 9AC’ represents the latest clinicalcandidate in a new class of antiviral agents, nucleic acid polymers (or NAPs) that block the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. Metadata analysis of patients on REP 9AC or REP 9AC’ demonstrates that serum HBsAg can be routinely eliminated in 12-16 weeks and is followed by a restoration in the patient’s immune response, resulting in a substantial elimination of virus from the blood of patients.  REPLICor will present updated clinical efficacy results and metadata analysis of antiviral responses in patients receiving REP 9AC or REP 9AC’ in an oral presentation on Sunday June 24th, 2012.
For the 14th International Symposium of Viral Hepatitis and Liver Disease see: http://www.isvhld2012.org/isvhld.html

咬牙硬挺

rep网站的新消息REPLICor to disclose interim REP 9AC / 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012)
22-25 June 2012, Shanghai International Convention Center, Shanghai,  China.
Montreal, Quebec – Friday, June 22nd, 2012 – REPLICor will disclose updated interim results and metadata analysis of antiviral responses in patients with chronic hepatitis B who are enrolled in its proof of concept clinical trials of REP 9AC and REP 9AC’for the treatment of chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012) currently being held from 22-25th of June.  This important meeting, held only once every three years, is the preeminent meeting focusing on viral hepatitis and attracts key academicians and physicians working to improve the treatment outlook for patients with viral hepatitis.
REP 9AC’ represents the latest clinicalcandidate in a new class of antiviral agents, nucleic acid polymers (or NAPs) that block the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. Metadata analysis of patients on REP 9AC or REP 9AC’ demonstrates that serum HBsAg can be routinely eliminated in 12-16 weeks and is followed by a restoration in the patient’s immune response, resulting in a substantial elimination of virus from the blood of patients.  REPLICor will present updated clinical efficacy results and metadata analysis of antiviral responses in patients receiving REP 9AC or REP 9AC’ in an oral presentation on Sunday June 24th, 2012.
For the 14th International Symposium of Viral Hepatitis and Liver Disease see: http://www.isvhld2012.org/isvhld.html

MP4

9AC怎么放这里了。

无语世界

价格多少，比恩替贵吗

StephenW

克拉夫定(Clevudine) - 他们将如何处理副作用？

MP4

StephenW 发表于 2012-7-23 19:00
克拉夫定(Clevudine) - 他们将如何处理副作用？

都有哪些-作用？

StephenW

回复 MP4 的帖子

克拉夫定的临床试验被停止由于副作用，主要是肌病(myopathy)。
以前曾有很多的讨论。
pharmasset自愿暂停克拉夫定在B型肝炎感染患者的临床研究 (may 2009)
http://www.natap.org/2009/HBV/060209_01.htm

MP4

StephenW 发表于 2012-7-23 19:30
回复 MP4 的帖子

克拉夫定的临床试验被停止由于副作用，主要是肌病(myopathy)。

替比也是咯，之前替比联合干扰就因为副作用。。。

干扰素副作用。。。。。。。。。。。
拉米耐药多，易复发，耐药株易癌变。
阿德肾风险，减3分1剂量才批。
恩替动物试验有致癌风险。
替诺是不是骨质疏松。